Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.
Top-line data from an international Phase 2b clinical trial evaluating ABX464, Abivax’s lead therapeutic candidate for moderate-to-severe ulcerative colitis (UC), are expected later this year, according to the company’s ... Read more
RedHill Biopharma’s experimental therapy RHB-104 significantly increases the remission and response rates of patients with Crohn’s disease, according to top-line Phase 3 trial results recently announced by the company. ... Read more
Newly discovered genetic alterations that precede the development of colorectal cancer associated with inflammatory bowel disease (IBD) may help in the development of diagnostic tools to identify patients at ... Read more
Regulators in Belgium have approved Abivax’s request for a long-term extension of the company’s ongoing Phase 2a trial of ABX464 as a treatment for ulcerative colitis. It said it expects approvals ... Read more
Protalix BioTherapeutics’ ulcerative colitis therapy OPRX-106 eradicated the disease in a third of the first 14 patients participating in a Phase 2 clinical trial. Fifty-seven percent of the patients responded to the ... Read more